Ombudsman: Quick resolution to complaints in 2006
This article was originally published in The Silver Sheet
Issues surrounding product adverse events, FDA inspections, warning letters and the Quality System Regulation accounted for 12 percent of complaints filed with CDRH's ombudsman last year, according to a recently published annual report. Ombudsman Les Weinstein received a total of 120 complaints from device manufacturers and others last year - roughly the same as in the previous three years. Eighty-one percent of the cases on Weinstein's desk last year were resolved. The resolution rate was significantly lower in prior years: 33 percent in 2005, 31 percent in 2004 and 26 percent in 2003. "Last year, a lot of cases to be resolved could be resolved quickly," Weinstein says. In addition, a number of cases that came to Weinstein's attention in 2004 and 2005 were finally resolved in 2006. As in previous years, "miscommunication" or "lack of communication" was the No. 1 reason for gripes to the ombudsman in 2006
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.